Related Experiment Videos
Etonitazene: an opioid selective for the mu receptor types
M S Moolten1, J B Fishman, J C Chen
1Department of Pharmacology, University of Massachusetts Medical Center, Worcester 01655.
Life Sciences
|January 1, 1993
Summary
Etonitazene, a potent opioid, shows significantly higher affinity for mu-1 receptors compared to morphine. This finding aligns with etonitazene
Area of Science:
- Pharmacology
- Neuroscience
- Receptor Binding Assays
Background:
- Opioid receptors (mu, delta, kappa) are critical targets for pain management.
- Morphine is a standard opioid analgesic, while etonitazene is a high-potency synthetic opioid.
- Understanding receptor affinity is key to predicting drug efficacy and side effects.
Purpose of the Study:
- To compare the binding affinities of morphine and etonitazene across multiple opioid and non-opioid receptor subtypes.
- To investigate the mu-1 receptor selectivity of both etonitazene and morphine.
- To correlate in vitro receptor binding data with known in vivo potencies.
Main Methods:
- Utilized specific radioligand binding protocols.
- Assessed binding affinity at mu-1, mu-2, delta, kappa-1, and sigma receptors.
- Compared etonitazene and morphine binding profiles.
Main Results:
- Both etonitazene and morphine exhibited a mu-1 selective binding profile.
- Etonitazene demonstrated a 2500-fold greater affinity for the mu-1 receptor compared to morphine.
- This significant difference in mu-1 affinity supports observed differences in behavioral potencies.
Conclusions:
- Etonitazene possesses markedly higher affinity for the mu-1 opioid receptor than morphine.
- The mu-1 receptor is a primary target for both etonitazene and morphine.
- Receptor binding data provide a strong basis for understanding the differential potencies of these opioids.